In an interview, Dr. David A. Taub highlighted Prostate Cancer Awareness Month by outlining current treatment options for patients with prostate cancer. In an interview with CURE, Dr. David A. Taub ...
A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate ...
Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23 January). NICE has recommended talazoparib ...
Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in ...
If you have been diagnosed with advanced prostate cancer, it's important to understand your treatment options. Your doctor will work with you to choose the optimal treatment approach. Your doctor can ...
PHOENIX — Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr.
An estimated 1 in 8 men will be diagnosed with prostate cancer in their lifetime, often after 65. And as terrifying as that number is, a diagnosis isn’t always quite what it seems. Today, the vast ...
You are at the center of everything we do at the Prostate Oncology Center at Fred Hutchinson Cancer Center. Here, we surround you with a team of specialists who work together closely to provide expert ...
A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...
Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, ...
Thousands of men with incurable prostate cancer will be offered a lifeline after an about-turn on NHS treatment.
John Yang: In other news tonight, former President Biden's office has announced that he's been diagnosed with an aggressive form of prostate cancer. The cancer spread to the bone and Mr. Biden and his ...